Search Results - t+cell

18 Results Sort By:
Affinity and Functional Based Screening of T Cell Receptor Repertoire Using Nanovials (Case No. 2024-042)
Summary: Researchers in the Department of Bioengineering at UCLA have developed a hydrogel platform that measures single T cell secretions, aiding in the definition of T cell receptor repertoires for functional immunotherapy applications. Background: T cell immunotherapies, namely T cell receptor (TCR) therapies, have emerged as promising candidates...
Published: 10/8/2024   |   Inventor(s): Dino Di Carlo, Owen Witte, Doyeon Koo, Zhiyuan Mao
Keywords(s): Cancer Immunotherapy, CAR-T cell therapy, Flow Cytometry, hydrogel, Immunooncology, Immunotherapy, Peptide, single cell analysis, T Cell, T cell based therapy
Category(s): Diagnostic Markers > Immunology, Life Science Research Tools > Screening Libraries, Therapeutics > Immunology And Immunotherapy
Targeting Serotonin Transporter (SERT) for Cancer Immunotherapy (UCLA Case No. 2024-204)
UCLA researchers in the Department of Microbiology Immunology and Molecular Genetics have unveiled a novel therapeutic strategy utilizing SSRIs for solid cancer immunotherapy. BACKGROUND: Immunotherapy has become a highly effective method to combat cancer that enhances a patient’s immune system to attack tumors with high specificity. For instance,...
Published: 6/18/2024   |   Inventor(s): Lili Yang
Keywords(s): Cancer, Immune checkpoint blockade, immune checkpoint inhibitors, Immunotherapy, selective serotonin reuptake inhibitors (SSRIs), serotonin, solid tumors, T Cell
Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy
Strategies to Detect, Prevent and Reverse Acquired Resistance to Immune Checkpoint Blockade Therapy (UCLA Case No. 2024-085)
UCLA researchers in the Department of Medicine have uncovered novel mechanism of acquired resistance against immune checkpoint blockade therapy in melanoma patients. BACKGROUND: Immune checkpoint blockade (ICB) therapy is a type of cancer immunotherapy that targets immune system components in order to reactivate immune cells to combat tumor cells....
Published: 5/8/2024   |   Inventor(s): Roger Lo
Keywords(s): acquired resistance, Apoptosis, Cancer, Cancer Immunotherapy, Immune checkpoint blockade, Immunotherapy, Melanoma, T Cell
Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy
Synthetic Viscoelastic Activating Cells (SynVACs) for T cell engineering (UCLA Case No. 2023-190)
UCLA researchers in the Department of Bioengineering have developed a novel microfluidic device that produces synthetic viscoelastic cells for efficacious therapeutic T cell activation. BACKGROUND: T cell-based therapies, such as the chimeric antigen receptor (CAR) T cell therapy, represents a significant advancement in cancer treatment, particularly...
Published: 11/15/2024   |   Inventor(s): Zeyang Liu, Song Li, Lili Yang, Yan-Ruide Li
Keywords(s): CAR-T cell therapy, Synthetic antigen presenting cells (SynVACs), T Cell, T cell based therapy, T-cell activation, T-cell engineering, t-cells
Category(s): Therapeutics > Oncology
Methods for Producing Stem Cell-Like Memory T Cells for Use in T Cell-Based Immunotherapies
Abstract: T cells currently employed for T cell-based immunotherapies are often senescent, terminally differentiated cells with poor proliferative and survival capacity. Recently, however, scientists at the National Cancer Institute (NCI) identified and characterized a new human memory T cell population with stem cell-like properties. Since these T...
Published: 9/26/2024   |   Inventor(s): Luca Gattinoni, Nicholas Restifo, Mario Roederer, Enrico Lugli
Keywords(s): anti-tumor activity, CANCER, Gattinoni, GSK-3beta, Immunotherapy, Infection, Stem Cell, T cell, WNT
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, Application > Therapeutics
Chimeric Antigen Receptor (CAR) that Targets Chemokine Receptor CCR4 and its Use in Treating Cancer
Abstract: The chemokine receptor, CCR4 is a seven transmembrane G protein-coupled cell surface receptor molecule with selective expression on cells of the hematopoietic system. In adult T cell leukemia (ATL), the cell-surface expression of CCR4 on leukemic cells has been found to be nearly universal. Therefore, a CCR4-directed chimeric antigen receptor...
Published: 4/8/2024   |   Inventor(s): Liyanage Perera, Thomas Waldmann
Keywords(s): Adult T Cell Leukemia, ALLOGENIC, ATL, CCR4, CD3+, Chemokine Receptor 4, Immunotherapy, Lymphoid Malignancy, mRNA, natural killer cell, NK, Perera, solid tumor, T cell
Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics
Inhibition of T Cell Differentiation and Senescence by Overexpression of Transcription Factor c-Myb
Abstract: Adoptive Cell Therapy (ACT) is a promising technique that uses a patient's own T cells to treat cancer. The process requires removing and engineering a patient's T cells to express a chimeric antigen receptor (CAR) or T cell receptor (TCR) that targets a specific cancer antigen. When the modified T cells are reintroduced into the patient,...
Published: 4/8/2024   |   Inventor(s): Sanjivan Gautam, Yun Ji, Luca Gattinoni
Keywords(s): act, Adoptive Cell Transfer, CANCER, CAR, chimeric antigen receptor, Gattinoni, Immunotherapy, Infectious Disease, Stem Cell, T cell, T Cell Receptor, TCR
Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing
IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 for Treating Liver Cancer
Abstract: Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Globally, HCC is the sixth most prevalent cancer and third leading cause of cancer-related morbidity. Standard treatment for HCC is not suitable for a large proportion of liver cancer patients. Part of this is because less than a quarter of HCC patients are surgical candidates...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Aarti Kolluri, Nan Li
Keywords(s): ANTIBODY, cancer therapeutic, Chimeric antigen receptors (CARs), Glypican-3 (GPC3), Hepatocellular Carcinoma (HCC), HO, IgG4, Liver cancer, Macrophage, NANOBODY, Natural Killer (NK) Cell, T cell, therapeutic
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
Overexpression of Phf19 on T Cells Enhances Therapeutic Effects of T Cell-Based Therapies (such as Chimeric Antigen Receptor [CAR] Therapies)
Abstract: T cell-based immunotherapy (such as CAR therapies) is a promising approach for the treatment of several cancers. However, T cells currently employed for various T cell-based immunotherapies are usually senescent and terminally differentiated leading to poor proliferative and survival capacity, limiting their therapeutic effectiveness once...
Published: 4/8/2024   |   Inventor(s): Yun Ji, Luca Gattinoni
Keywords(s): CAR-T Therapy, CD8, chimeric antigen receptor, Gattinoni, Phf19, T cell
Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics
Novel Cancer Immunotherapy: A T Cell Receptor That Specifically Recognizes Common KRAS Mutations
Abstract: Several malignancies associated with a poor prognosis such as lung, pancreatic and colorectal cancers frequently harbor constitutively active KRAS mutants, which play a pivotal role in oncogenesis.  Currently, there are no potentially curative treatments against most mutant KRAS harboring cancers once they become metastatic and unresectable. ...
Published: 4/8/2024   |   Inventor(s): Qiong Wang, James Yang, Zhiya Yu
Keywords(s): Colorectal, Immunotherapy, KRAS, LUNG, oncogenesis, PANCREAS, PROSTATE, T cell, TCR
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
1 2